A small Life Sciences organization had an established product in the Oral CGRP market focused on acute treatment of migraines.
Fifteen months post launch, the brand received an additional indication for the preventative treatment of episodic migraines.
PROPENSITY4 was able to deliver a final targeting scheme in 8 weeks, marrying primary and secondary data to create an informed targeting approach.
The brand was able to deliver 4x the forecast across both indications in a highly genericized market.
CASE STUDY (US) Combining tactics, insights, and business strategy drives significant growth in Women's Healthcare launch.
Read moreSupporting a new European division to launch brands in eight markets.
Read moreClient’s specialty product had a complicated oral therapy regimen requiring supplemental support to patients...
Read more